Nessan Bermingham (file photo)

An­i­mal da­ta in hand, Nes­san Berming­ham banks $91.5M for At­las-backed RNA edit­ing play

Ko­r­ro Bio, the RNA edit­ing start­up that got start­ed on $4 mil­lion in seed fund­ing from At­las and some more cash from New En­ter­prise As­so­ciates, has brought in $91.5 mil­lion for its Se­ries A haul.

Un­der ex­ec­u­tive chair­man Nes­san Berming­ham, the biotech has racked up an­i­mal da­ta that he said show “pret­ty high tar­get­ed edit­ing straight out of the gate.” Off-tar­get ac­tiv­i­ty wasn’t an is­sue, and the OPERA plat­form ap­peared able to ze­ro in on mul­ti­ple types of RNA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.